| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1030325462 |
| P356 | DOI | 10.1038/SJ.ONC.1201250 |
| P698 | PubMed publication ID | 9285690 |
| P5875 | ResearchGate publication ID | 239444475 |
| P2093 | author name string | Yu D | |
| Hung MC | |||
| Ueno NT | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Adenoviridae | Q193447 |
| paclitaxel | Q423762 | ||
| overexpression | Q61643320 | ||
| P304 | page(s) | 953-960 | |
| P577 | publication date | 1997-08-01 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. | |
| P478 | volume | 15 |
| Q43973697 | A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma |
| Q37665524 | A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer |
| Q37381467 | A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. |
| Q34051930 | Abcc10 status affects mammary tumour growth, metastasis, and docetaxel treatment response |
| Q34200411 | Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation |
| Q34048741 | Anti-tumor function of double-promoter regulated adenovirus carrying SEA gene, in the treatment of bladder cancer |
| Q40371761 | Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. |
| Q36649565 | Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. |
| Q40737438 | Cancer therapy utilizing an adenoviral vector expressing only E1A. |
| Q36226789 | Cancer-specific gene therapy. |
| Q40897772 | Characterization of a repressor element and a juxtaposed tissue-restricted activator element located on the distal neu gene promoter |
| Q34786501 | De-acetylation and degradation of HSPA5 is critical for E1A metastasis suppression in breast cancer cells |
| Q34273680 | Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy |
| Q44533984 | EBNA1 may prolong G(2)/M phase and sensitize HER2/neu-overexpressing ovarian cancer cells to both topoisomerase II-targeting and paclitaxel drugs |
| Q34750374 | Emerging new therapies for chemotherapy-resistant cancer using adenoviral vectors |
| Q40493718 | Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer |
| Q35007782 | Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer |
| Q37010568 | Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. |
| Q39172262 | Expression of the Adenovirus Early Gene 1A Transcription-Repression Domain Alone Downregulates HER2 and Results in the Death of Human Breast Cancer Cells Upregulated for the HER2 Proto-Oncogene |
| Q35622770 | FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization |
| Q35213246 | Gene therapy for ovarian cancer: progress and potential |
| Q34882099 | HER-2 in breast cancer--methods of detection, clinical significance and future prospects for treatment |
| Q50643855 | HER2 positivity may confer resistance to therapy with paclitaxel in breast cancer cell lines. |
| Q34560682 | Head and neck cancer: gene therapy approaches. Part II: genes delivered |
| Q34170177 | Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis |
| Q81380006 | Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells |
| Q40582648 | Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER -2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere). |
| Q24553135 | Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer |
| Q57174025 | Oncolytic virus and PD-1/PD-L1 blockade combination therapy |
| Q33931164 | Overexpression of ErbB2 in cancer and ErbB2-targeting strategies |
| Q33411110 | Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation |
| Q36355240 | Polylactide-based paclitaxel-loaded nanoparticles fabricated by dispersion polymerization: characterization, evaluation in cancer cell lines, and preliminary biodistribution studies |
| Q35923996 | Regulation of the activity of p38 mitogen-activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis |
| Q40921389 | Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin |
| Q34711378 | Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer |
| Q33932784 | αB-crystallin promotes oncogenic transformation and inhibits caspase activation in cells primed for apoptosis by Rb inactivation |
Search more.